Endothelium has been thought to play a passive role in hemostatic and inflammatory phenomena. Clinical and laboratory observations, however, have suggested that endothelium can play an active role in the response of the inflammatory and coagulation systems to perturbation and that these responses are linked. A component of the delayed hypersensitivity response, for example, includes induction of procoagulant activity (I). The Shwartzmann reaction, a basic phenomenon in the biology of bacterial infections, includes tissue infiltration by leukocytes and prominent thrombotic pathology. Another example is the clinical picture of systemic lupus erythematosus, which includes a vascutitic syndrome and multiple coagulation abnormalities in addition to autoimmune phenomena (2).
199 containing bovine serum albumin (fatty acid free) (0.5%) and polymyxin B (1 ~g/ml) before use.
IL-1 and IL-2 Assays. IL-1 activity was measured in a costimulator assay using routine thymocytes as described previously (23) . In brief, thymocytes (1.5 × 106/well) from 4-8-wk-old C3H/HEJ mice (The Jackson Laboratory, Bar Harbor, ME) were cultured for 72 h in Iscoves modified Dulbecco's medium (Gibco Laboratories) containing fetal calf serum (10%), glutamine (1%),/3-mercaptoethanol (50 t~M), and phytohemagglutinin (1%). Supernatant (50 #l) from stimulated endothelial cells was added to each well at the start of a 72 h assay, and [3H]thymidine (1 uCi/well; New England Nuclear, Boston, MA) was added 18 h before harvesting. Before assaying supernatants of endothelial cells containing added cycloheximide, samples were extensively dialyzed vs. saline (dialysis tubing had a molecular weight cut-offof 3,500). Control samples containing cycloheximide and medium not exposed to cells were also dialyzed and assayed. Under these conditions cycloheximide had no effect on thymocyte proliferation in response to added IL-1 (Genzyme, Boston, MA). In addition to studying culture supernatants, a lysate of endothelial cells was also assayed. The lysate was prepared by three freeze-thaw cycles (-80 to 37°C) and cellular debris was removed by centrifugation (10,000 g for 20 rain). Samples were assayed in triplicate. Lipopolysaccharide, up to 100 t~g/ml, did not induce thymocyte proliferation above background in this assay. Culture supernatants containing added thrombin were treated with a 100-fold molar excess of purified bovine antithrombin III (see below) to inactivate any residual thrombin activity. Thrombin, however, even at the highest doses used (40-50 U/ml) had only a minimal effect on the thymocyte proliferation assay. The latter effect was abrogated by the addition of antithrombin III. Antithrombin III alone did not induce proliferation of murine thymocytes or affect proliferation of thymocytes induced by purified IL-1 (Genzyme). Antitbrombin III and diisopropyl fluorophosphate had no effect on endotoxininduced IL-1 elaboration by endothelial cells (see below). DIP-a-thrombin, 3,-thrombin, and ~-Phe-Pro-Arg-CH2-a-thrombin (see below) had no direct effect on the thymocyte proliferation assay at the concentrations used in these experiments.
IL-2 activity was assessed by measuring proliferation of the murine IL-2-dependent CTLL-2 line (the characteristics of this cell line have been previously described) (24) (25) induced by addition of supernatants from stimulated and control endothelial cells. The assay was carried out by incubating CTLL-2 cells 004 ceils per well) in the presence or absence of endothelial cell supernatants for 48 h, then adding [3H]thymidine (1 #Ci/well) and harvesting 18 h later. No IL-2 activity was detectable in control or stimulated endothelial cell supernatants.
Preparation of Coagulation Proteins and Tissue Factor Assay. Human factors IX (250 U/ rag) and X (130 U/mg) were purified to homogeneity from plasma by the method of DiScipio et al. (26) . Factor IX was activated, as previously described (27) , during incubation with factor XL coupled to Sepharose in the presence of CaCl2 (5 mM) for 45 rain at 37 °C. Factor X was activated during incubation with the coagulant protein from Russell's viper venom coupled to Sepharose in the presence of CaClz (5 raM) for 30 rain at 37°C as previously described (28) . In each case activation appeared complete by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Human prothrombin and human factor VIL were purified to homogeneity, as described previously (29) (30) . Bovine antithrombin III (inhibitory activity of 1.0 U thrombin/#g) was purified to homogeneity by the method of Mahoney et al. (31) . Human a-thrombin (2.5 NIH U/#g) was purified as described (32) . a-Thrombin was inactivated by incubation with diisopropylfluorophosphate (33) (2 mM at pH 7.5; Calbiochem-Behring Corp., San Diego, CA) for 20 min at 37°C. The reaction mixture was then dialyzed extensively vs. Hepes-saline [10 mM (pH 7.4)/0.14 M]. A coagulant assay (34) indicated no residual thrombin activity. Thrombin (0.15 #g/ml) was also completely inactivated by antithrombin I II (250 ug/ml) after 10 min at 37 °C (35). 7-Thrombin and D-Phe-Pro-Arg-CHz-a-thrombin were prepared as described (36) . Tissue factor activity of endothelial cell monolayers was assessed after washing the cells three times in Hepes-saline by adding factor VIL (0.5 nM) and factor X (300 nM) in 10 mM Hepes (pH 7.4), 137 mM NaCI, 4 mM KC1, 11 mM glucose, 2.5 mM CaCI2, 2 mg/ ENDOTHELIAL CELL ELABORATION OF INTERLEUKIN 1 ml bovine serum albumin at 37 °C. Aliquots of the reaction mixture supernatant (0.1 ml) were withdrawn at 7 rain, diluted in 0.5 ml of 50 mM Tris-HCl (pH 7.8), 175 mM NaCI, 0.5 mg/ml ovalbumin, 10 mM EDTA, and assayed for factor Xa amidolytic activity. Amidolytic activity was measured using the synthetic substrate Bz-Ile-Glu-Gly-Arg-pNA (0.5 mM) by monitoring the increase in absorbance at 405 nM (37) . The concentration of factor X, formed was determined by comparison with a factor Xa standard as described previously (28) . Under these conditions, factor Xa formation was linear and limited only by the amount of tissue factor present. Before assaying cells treated with thrombin, the added thrombin was neutralized by excess antithrombin III and monolayers were then washed to remove antithrombin III. Similar results were observed when dansylarginine N-(3-ethyl-l,5-pentanediyl)amide, a specific thrombin inhibitor (38) , replaced antithrombin III.
Results
Incubation of cultured human umbilical vein endothelial cells with lipopolysaccharide resulted in the elaboration of IL-1 activity (Fig. 1) . The IL-1 activity of supernatants from lipopolysaccharide-treated endothelial cells was easily detectable up to a 1:32 dilution in the murine thymocyte costimulation assay. Although the thymocyte assay was sensitive for the detection of endothelial cell IL-1 activity, to better characterize the molecular species in the supernatants causing the proliferative response, we used an affinity column with anti-IL-1 antibody coupled to Sepharose (Fig. 2) . Chromatography of lipopolysaccharidetreated endothelial cell supernatants on the anti-IL-1 column removed their proliferative activity in the thymocyte assay. A control column, with nonimmune IgG coupled to the resin, had no effect on IL-l-like activity in the culture supernatants.
Generation of IL-1 activity was dependent on the concentration of lipopolysaccharide added, increasing steadily from 10 ng/ml to 10 ~g/ml and, soon thereafter, reaching an apparent maximum (Fig. 3A) . IL-1 found in the super- 15 30 cpm X 10 -3 FIGURE 2. Effect of anti-lL-1 column on the IL-1 activity of lipopolysaccharide-treated endothelial cell supernatants. Endothelial cell monolayers (passage 4) were incubated with medium 199 (1 ml) containing fetal calf serum (2%) in the presence of endotoxin (10 ~g/ml) for 18 h at 37°C. Aliquots of culture supernatants (0.2 ml) were then chromatographed on an anti-lL-1 column (bed volume, 0.8 ml) or a column made by coupling nonimmune rabbit IgG to the resin (bed volume, 0.8 ml). The initial culture supernatant (A), pass-through fraction from the anti-IL-1 column (B), and pass-through fraction from the control IgG column (C) were assayed in the thymocyte proliferation assay. The mean _+ 1 SD of triplicate determinations is shown. natant was not due to release from a preformed intracellular pool since lysates of endothelial cells not treated with lipopolysaccharide did not have significant I L-1 activity. To investigate whether protein synthesis was required for induction of IL-1 release, we added cycloheximide to cultures during lipopolysaccharide stimulation (Fig. 4) . Inhibition of IL-1 production was observed in the presence of cycloheximide (1 ug/ml), indicating that new protein synthesis was required.
Comparable lipopolysaccharide-induced generation of IL-1 activity was observed with endothelial cells from four different vessels, using both primary cultures and serially passaged cells (passages 1-18). Furthermore, endotoxintreated bovine aortic and capillary endothelial cells also generated IL-1 activity, though the amounts were lower (~30%) than that observed with the human umbilical vein endothelial cells (data not shown). Elaboration of IL-1 activity occurred in a time-dependent manner after the addition of lipopolysaccharide to endothelial cultures (Fig. 3B) . IL-1 activity steadily increased up to 16 h and . This concentration of cyclobeximide did not reduce cell viability. Culture supernatants were dialyzed extensively vs. saline and assayed for IL-1 as described. Addition of lipopolysaccharide (10 ~g/ml) directly to the IL-1 assay (D) resulted in little thymocyte proliferation. Cycloheximide (1 pg/ml), after dialysis, bad no effect on the thymocyte proliferation assay (E). The mean -+ 1 SD is shown.
then reached a plateau. In contrast, control endothelial cell cultures in media alone maintained a low level of IL-1 activity.
Since endothelial cells do not usually interact with lipopolysaccharide, we asked if any more physiological molecules could induce endothelial cell IL-1 elaboration. Prompted by recent studies demonstrating specific interactions between endothelium and coagulation factors (9, 28, 40-45), we examined the effect of a variety of coagulation proteins on endothelial cell IL-1 elaboration (Table I) . These studies were carried out in serum-free medium to prevent inactivation of activated coagulation factors by inhibitors present in serum, such as antithrombin IlI. Coagulation factors normally present in plasma, i.e., the zymogens, factors IX, X, and prothrombin (added at plasma concentrations), did not induce generation of IL-1 activity by endothelial cells. Although the activated form of factors IX (IXa) and X (Xa), induced no or only small amounts of IL-1 release, respectively, thrombin induced elaboration of significant amounts of IL-1. To further study the effect of thrombin on endothelial cell elaboration of IL-1, we used thrombins modified at specific sites (Table II) . Native ~-thrombin induced elaboration of IL-1 endothelium, but tbrombin inactivated by antithrombin III was no longer effective. Since antithrombin III is a relatively large molecule (M~ ~58,000) (31, 35) compared with thrombin (Mr -36,500) (32), the inhibitor could be masking muhiple sites on the enzyme in addition to the active site. This led us to examine the effect of other forms of thrombin. ~{-thrombin (36), a form of thrombin deficient in procoagulant activity but which retains estero]ytic activity, was less effective than c~-thrombin in the induction of IL-1. D-Phe-ProArg-CH2-c~-thrombin (36), which is modified just adjacent to the catalytic site within the fibrinopeptide groove (39), did not induce endothelial cell IL-I elaboration. Consistent with this data, which suggests the importance of the active site region of o~-thrombin, we found that DIP-a-thrombin, which has a blocked catalytic center, was ineffective in the induction of endothelial cell IL-1.
Endothelial cell IL-1 elaboration induced by c~-thrombin was dependent on the concentration of enzyme added and the incubation time (Fig. 5) . The time course of IL-1 elaboration was comparable to that observed with lipopolysaccha- Endothelial cells (passage 3) were incubated with medium 199 containing bovine serum albumin (0.5%) and polymyxin B (1 gg/ml). Then coagulation factors at the indicated concentrations were added for 16 h at 37 ° C. Cultures containing factor X~ and thrombin were incubated with antithrombin Ill (400 ug/ml) for 10 rain at 37°C and then all samples were assayed in the thymocyte proliferation assay. The mean _ 1 SD is shown. * Factors IX~ and Xa are the activated forms of factors IX and X, respectively. Endothelial cells (passage 6) were incubated with medium 199 containing fetal calf serum (2%) and polymyxin B (1 mg/ml). One of the following thrombins was added for 16 h at 37°C: a-Thrombin (0.3 U/ml or 0.12 ug/ml), a-thrombin (0.15 #g/.ml) inactivated by antithrombin lit (250 ~g/ ml), ~-thrombin (0.2 ug/ml), ~Phe-Pro-Arg-CH2-c~-thrombin (0.18 ug/ ml), and DIP-c~-thrombin (0.11 ug/ml). Samples were assayed in a thymocyte proliferation assay. Control endothelial cell monolayers not incubated with any form of thrombin incorporated 1,400 ___ 350 cpm of [3H]-thymidine. Modified forms of thrombin were prepared as described in Materials and Methods.
TABLE II

Effect of a-Thrombin and Modified Thrombins on the Induction of IL-1 Activity in Endothelial Cells
ride. Although the amount of thrombin causing optimal IL-1 elaboration is relatively high, IL-1 is generated at lower concentrations, which may occur as prothrombin is generated on the endothelial cell surface (9, 28, 43) . IL-1 activity Dependence on dose of a-thrombin. Endothelial cell monolayers (passage 5) were incubated for 16 h at 37°C with medium 199 (1 ml) containing 0.5% bovine serum albumin, polymyxin B (1 gg/ml), and the indicated concentrations of thrombin. A 100-fold molar excess of bovine antithrombin III was then added to each culture dish for 10 rain at 37°C and supernatants were assayed in the thymocyte proliferation assay. The direct effect of thrombin (50 U/ml), in the absence of endothelial cell supernatants, on proliferation in the thymocyte assay is shown (a). (B) Time course of a-thrombin-induced elaboration of IL-1. Endothelial cell monolayers were incubated for the indicated times at 37°C with medium 199 (1 ml) containing 0.5% bovine serum albumin (fatty acid free) and polymyxin B (1 #g/ml) in the presence (0) or absence (I) of thrombin (5 U/ml). Antithrombin Ill (0.8 rnM) was added for 10 rain and then supernatants were assayed in the thymocyte proliferation assay. The mean + SD is shown.
produced by endothelial cells in response to thrombin could be removed from culture supernatants by the anti-IL-1 column, as described previously for lipopo]ysaccbaride-induced IL-1 activity (Fig. 2) . Thrombin-induced IL-1 generation was not due to lipopolysaccharide in the preparation since addition of antithrombin III or treatment of the enzyme with diisopropyl fluorophosphate blocked the enzyme's effect. Furthermore, treatment of lipopolysaccharide with antithrombin III or diisopropyl fluorophosphate under these conditions did not affect endotoxin-induced IL-1 elaboration.
These results indicate that a potent procoagulant enzyme, thrombin, can induce IL-1 in a highly specific manner. Since IL-1 is known to induce tissue factor activity in cultured endothelial cells (7), this suggested the possibility of self-regulation of procoagulant events on the endothelial cell surface. To test this hypothesis, IL-l-containing supernatants from endothelial cells treated with thrombin were incubated with fresh cultures, after the residual thrombin was inactivated, and induction of tissue factor activity was tested (Fig. 6 ). Procoagulant activity, characterized as tissue factor based on the factor VIIa dependence of factor X activation (8), was induced in endothelium. Similar induction of tissue factor activity was observed when cultures were incubated with exogenous IL-1 (Fig. 6) . The ability of both a-thrombin-treated endothelial cell supernatants and exogenous IL-1 to induce tissue factor in endothelial cells was prevented by chromatography of the samples on the anti-IL-1-Sepharose column.
Discussion
The results reported here indicate that cultured endothelial cells elaborate ILl in response to perturbation. Generation of IL-I activity in response to endotoxin suggests that endothelium participates in the regulation of inflammatory/ . Effect of culture supernatants from thrombin-treated endothelial cells on the procoagulant activity of fresh endothelial cell cultures. Human endothelial cell monolayers (passage 3) were treated with a-thrombin (10 U/ml) in medium 199 containing bovine serum albmnin (0.5%) and polymyxin B (1 txg/ml) for 8 h at 37°C. After this incubation period the supernatant (endothelial cell-conditioned medium) was incubated with antithrombin III (2 uM) (10 min at 37°C) to inactivate residual thrombin, filtered (0.22 t~m), and added to fresh endothelial cells for 6 h. Monolayers were washed and then 1 ml of 10 mM Hepes (pH 7.4) containing 137 mM NaCI, 4 mM KCI, 11 mM glucose, 2.5 ml CaCI~, 2 mg/ml bovine serum albumin, along wtih human factor Vlla (0.5 nM) and/or factor X (300 nM), was added for 7 min at 23°C. The reaction mixture was assayed for factor Xa amidolytic activity using the synthetic peptide substrate Bz-lle-Glu-Gly-Arg-p-nitroanilide (0.5 mM). The amount of factor Xa formed after 7 rain (mean _+ SEM) is shown. (A) Endothelial cell-conditioned medium was incubated with the cells and factor Xa formation was assessed in the presence of factors VIIa and X. (B) Endothelial cell-conditioned medium was incubated with the cells and factor X~ formation was assessed in the presence of factor X alone. (C) Medium 199 containing thrombin (10 U/ml) was incubated for 8 h in a glass tube and then antithrombin III (2 #M) was added to inactivate the thrombin. This medium (1 ml) was then incubated with the cells for 6 h at 37°C and factor Xa formation was assessed in the presence of factors VII~ and X. (D, E) Medium 199 containing purified exogenous IL-1 (5 U/ml, D; I U/ml, E) (supplied in 5% fetal calf serum) was incubated with endothelial cells, and factor Xa formation was assessed in the presence of factors VII~ and X. The mean and SEM of triplicates are shown.
immunologic phenomena. The induction of endothelial cell IL-1 activity by thrombin indicates a link between activation of the coagulation system and the regulatory role of the endothelial cell. Although quiescent endothelium does not induce activation of coagulation, perturbation of endothelial cells in vitro by a variety of agents, including IL-1, can lead to the induction of tissue factor, a cofactor for the initiation of coagulation (8) . Endothelial cell tissue factor, in the presence of factor VII/VIIi, results in the activation of factors IX and X, propagating a procoagulant pathway on the cell surface that leads to the generation of thrombin (9, 28) . Thrombin may then function as a coagulation enzyme or as a regulator of endothelial cell function, including the elaboration of IL-1. IL-1, finally, promotes the synthesis and expression of additional endothelial cell tissue factor. Although multiple pathways are operative in inhibiting thrombin procoagulant activity in the plasma and on the endothelial cell surface (28, 33, 35, (44) (45) (46) (47) , thrombin-induced IL-1 generation represents a cellular mechanism by which this enzyme can potentially promote procoagulant events. The induction of IL-1 activity by thrombin was specific for the enzyme (Tables  I and II) and required an intact catalytic center. Thus, DIP-o~-thrombin and DPhe-Pro-Arg-o~-thrombin (36) did not induce IL-1 elaboration but a-thrombin did (Table II) . 3,-thrombin, in which the fibrin exosite region is blocked (39), was able to induce IL-1, though less effectively than the intact enzyme. This is consistent with many of thrombin's cellular actions, such as stimulation of mitogenesis (48) and prostaglandin synthesis (49), but differs from thrombin's role as a chemotactic agent (39) in which DIP-a-thrombin is even more effective than the active enzyme. Thrombin-induced IL-1 generation may be related to the previously described (45) class of irreversible endothelial cell binding sites specific for the enzyme. Other mechanisms may be involved, such as thrombinprotease nexin complexes (50) or thrombin-induced proteolysis of the IL-1 translation product (51, 52) to potentially more active forms. The role of thrombin as an inducer of IL-1 suggests that activation of coagulation can play a role in priming the immune and inflammatory response. Thus, in addition to the well-known activation of coagulation leading to fibrin deposition, observed in a range of inflammatory lesions, a product of the coagulation system, thrombin, can play a role in the regulation of the inflammatory response.
The present data reflect the close relationship between the hemostatic and inflammatory systems. Perturbation of endothelium by stimuli such as IL-1 leads to induction of tissue factor procoagulant activity. Tissue factor promotes initiation of coagulation by priming the reactions leading to thrombin formation. Thrombin, by inducing endothelial cell IL-1 production, closes a circle of interactions between the inflammatory and coagulation systems.
Summary
Interleukin 1 (IL-1) is a potent mediator of inflammatory and immunologic phenomena. In addition, IL-I may be intimately involved in the regulation of hemostasis, since interaction of IL-1 with endothelial cells has been reported to induce tissue factor activity. We demonstrate that perturbation of the endothelial cell induces augmented IL-1 release. Human umbilical vein endothelial cells perturbed by treatment with lipopolysaccharide produced enhanced amounts of IL-1 activity. IL-1 activity from lipopolysaccharide-treated endothelial cell supernatants could be absorbed by an antibody to IL-1 coupled to Sepharose. Elaboration of IL-1 activity was dependent on the dose of lipopolysaccharide and occurred in a time-dependent manner. Addition of cycloheximide blocked generation of IL-I activity. A physiological vessel wall perturbant, the coagulation enzyme thrombin, induced comparable amounts of IL-1 activity in endothelial cell cultures. This effect was specific for the enzyme, since active site-blocked thrombin and prothrombin had no effect on IL-1. In addition, IL-l-containing supernatants from thrombin-stimulated endothelial cells induced tissue factor procoagulant activity in fresh endothelial cell cultures. Thus, in contrast to the multiple, known inhibitory mechanisms that block thrombin procoagulant activity, these data suggest a circle of interaction in which thrombin induces endothelial cell elaboration of IL-1, a mediator of endothelial cell procoagulant activity. Endothelial cell production of IL-1 in response to perturbation allows these cells to play an integral role in the regulation of the inflammatory and coagulation systems.
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